Histofy and Leica Biosystems Announce Global Reseller Agreement for AI-Powered Pathology Solutions
Coventry, UK and Vista, CA– 6 Sep 2025 – Histofy, a leading innovator in AI-powered pathology, today announced a customer-centric collaboration with Leica Biosystems, a global leader in anatomic and digital pathology solutions. Under this agreement, Leica Biosystems will act as a reseller and incorporate Histofy’s AI solutions, starting with MitPro®, Histofy’s next-generation mitosis profiling tool, into the Aperio AI Store, an analysis platform providing access to a curated menu of leading AI tools.
MitPro® harnesses advanced cutting-edge AI to detect and profile mitotic figures across H&E-stained tissue slides in 10 different cancers, addressing one of the most labour-intensive and variable tasks in pathology. The tool automatically identifies mitotic hotspots, provides reproducible counts and densities, and integrates seamlessly with Leica Biosystems Aperio HALO AP image management platform.
By combining Histofy’s cutting-edge AI technology with Leica Biosystems global reach and expertise in digital pathology, the partnership will deliver scalable, integrated solutions to accelerate adoption of AI in pathology research and clinical development.
Key Highlights of MitPro®:
- Automated detection of mitotic figures across whole-slide images.
- Identification of the three highest-scoring hotspots with scoring metrics.
- Pathologist verification with options to add or remove figures.
- Application across a wide range of cancers, including breast, lung, melanoma, sarcomas, and glioblastoma.
- Seamless integration with Aperio HALO AP, ensuring minimal workflow disruption.
- For Research Use Only. Not for clinical diagnostic use.
Professor Nasir Rajpoot, CEO of Histofy, said:
“Our mission at Histofy is to empower pathologists with AI tools that enhance accuracy, efficiency, and reproducibility. Partnering with Leica Biosystems allows us to bring MitPro® to a global audience within their trusted workflows, marking an important milestone in advancing digital pathology.”
“We are excited to partner with Histofy to have their applications on the Aperio AI Store,” said Naveen Chandra, Vice President and General Manager of Digital Pathology at Leica Biosystems. “We recognize that the seamless integration of leading innovative analysis solutions into Aperio HALO AP enabling users to view all their data, images, and AI results in one place, is key to driving AI-enabled assays to ultimately improve patient diagnoses and care.”
This agreement underscores the growing role of AI in pathology and reinforces the shared vision of Histofy and Leica Biosystems to transform cancer diagnostics and improve patient outcomes with advanced digital platforms and AI tools.
About Histofy
Histofy is a pioneering spinout from the University of Warwick, dedicated to developing AI-powered solutions that supercharge digital pathology workflows. Its products span clinical research, pharma, and toxicologic pathology, offering robust, data-driven insights to improve diagnostic efficiency and patient outcomes.
About Leica Biosystems
Leica Biosystems is a cancer diagnostics company and a global leader in anatomic and digital pathology solutions. The company offers a comprehensive product range for each step in the pathology process, from sample preparation and staining to imaging and reporting. As the only company to own the full workflow from biopsy to diagnosis, Leica Biosystems is uniquely positioned to break down the barriers between each step. The company’s mission of “Advancing Cancer Diagnostics, Improving Lives” is at the heart of its corporate culture. Leica Biosystems is proud to be a Danaher Corporation subsidiary.
